SynthesisCanadian journal of gastroenterology = Journal canadien de gastroenterologie2013
Diagnostic value of stool DNA testing for multiple markers of colorectal cancer and advanced adenoma: a meta-analysis.
Synthesis in Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pooled it
- Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis.Journal of gastrointestinal cancer · 2016Pooled it
- The Diagnostic Performance of Stool DNA Testing for Colorectal Cancer: A Systematic Review and Meta-Analysis.Medicine · 2016Pooled it
- Pooled it
- TH1L involvement in colorectal cancer pathogenesis by regulation of CCL20 through the NF-κB signalling pathway.Journal of cellular and molecular medicine · 2024Article
- The methylation of SDC2 and TFPI2 defined three methylator phenotypes of colorectal cancer.BMC gastroenterology · 2022Article
- Stool DNA test targeting methylated syndecan-2 (SDC2) as a noninvasive screening method for colorectal cancer.Bioscience reports · 2021Article
- Feasibility of MethylatedFrontiers in oncology · 2021Article
- Relationship betweenAnnals of medicine and surgery (2012) · 2020Article
- Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening.Cancer medicine · 2019Article
- Gene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencing.World journal of gastroenterology · 2017Article
- In vivo endoscopic Doppler optical coherence tomography imaging of the colon.Lasers in surgery and medicine · 2017Article
- Case-control study of candidate gene methylation and adenomatous polyp formation.International journal of colorectal disease · 2017Article
- Observational
- Identification of Epigenetic Biomarkers of Lung Adenocarcinoma through Multi-Omics Data Analysis.PloS one · 2016Article
- Review
- Direct Reading of Bona Fide Barcode Assays for Diagnostics with Smartphone Apps.Scientific reports · 2015Article
- DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer.Biochemical and biophysical research communications · 2014Review
- Epigenetic Biomarkers for the Early Detection of Gastrointestinal Cancer.Gastrointestinal tumors · 2014Review
- Circulating and stool nucleic acid analysis for colorectal cancer diagnosis.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe diagnostic value of stool DNA (sDNA) testing for colorectal neoplasms remains controversial. To compensate for the lack of large-scale unbiased population studies, a meta-analysis was performed to evaluate the diagnostic value of sDNA testing for multiple markers of colorectal cancer (CRC) and advanced adenoma.
methodsThe PubMed, Science Direct, Biosis Review, Cochrane Library and Embase databases were systematically searched in January 2012 without time restriction. Meta-analysis was performed using a random-effects model using sensitivity, specificity, diagnostic OR (DOR), summary ROC curves, area under the curve (AUC), and 95% CIs as effect measures. Heterogeneity was measured using the χ(2) test and Q statistic; subgroup analysis was also conducted.
resultsA total of 20 studies comprising 5876 individuals were eligible. There was no heterogeneity for CRC, but adenoma and advanced adenoma harboured considerable heterogeneity influenced by risk classification and various detection markers. Stratification analysis according to risk classification showed that multiple markers had a high DOR for the high-risk subgroups of both CRC (sensitivity 0.759 [95% CI 0.711 to 0.804]; specificity 0.883 [95% CI 0.846 to 0.913]; AUC 0.906) and advanced adenoma (sensitivity 0.683 [95% CI 0.584 to 0.771]; specificity 0.918 [95% CI 0.866 to 0.954]; AUC 0.946) but not for the average-risk subgroups of either. In the methylation subgroup, sDNA testing had significantly higher DOR for CRC (sensitivity 0.753 [95% CI 0.685 to 0.812]; specificity 0.913 [95% CI 0.860 to 0.950]; AUC 0.918) and advanced adenoma (sensitivity 0.623 [95% CI 0.527 to 0.712]; specificity 0.926 [95% CI 0.882 to 0.958]; AUC 0.910) compared with the mutation subgroup. There was no significant heterogeneity among studies for subgroup analysis.
conclusionsDNA testing for multiple markers had strong diagnostic significance for CRC and advanced adenoma in high-risk subjects. Methylation makers had more diagnostic value than mutation markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.